nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-206-10-147-151nogr-2170Research ArticleCOVID-19COVID-19Гастроэнтерологические поражения у пациентов с COVID-19Gastroenterological disorders in patients with COVID-19ШаробароВ. И.SharobaroV. I.noemail@neicon.ruМаликВ. В.MalikV. V.lera.bartyshova@mail.ruКорналевскаяВ. А.KornalevskayaV. A.noemail@neicon.ruФедеральное государственное бюджетное образовательное учреждение высшего образования «Смоленский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияSmolensk State Medical UniversityRussian Federation202218012023010147151Copyright © Шаробаро В.И., Малик В.В., Корналевская В.А., 20232023Шаробаро В.И., Малик В.В., Корналевская В.А.Sharobaro V.I., Malik V.V., Kornalevskaya V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/2170

Введение - Установлено, что частота возникновения симптомов со стороны желудочно-кишечного тракта (ЖКТ) при инфекции COVID-19 варьируется в пределах 11,4-50. Сообщается о случаях манифестирования заболевания с гастроэнтерологических симптомов, проявляющихся в среднем за 1-5 дней до развития респираторных симптомов. Описано течение заболевания с наличием диареи и рвоты без повышения температуры и других классических проявлений. Цель - провести обзор научной литературы, посвященной анализу ведущих патогенетических факторов формирования кишечного синдрома при новой коронавирусной инфекции. Материал и методы. Проведен поиск научной литературы в базах данных Web of Science, Scopus, PubMed и РИНЦ по следующим ключевым словам: коронавирусная инфекция, кишечный синдром. Глубина поиска - 3 года. Результаты.Исследование выявило клинические проявления со стороны желудочно-кишечного тракта (ЖКТ) при инфекции COVID-19 их основные механизмы и частоту встречаемости тех или иных симптомов в практической деятельности.

Introduction - It was found that the frequency of symptoms from the gastrointestinal tract (gastrointestinal tract) in COVID-19 infection varies between 11.4-50. Cases of manifestation of the disease with gastroenterological symptoms are reported, appearing on average 1-5 days before the development of respiratory symptoms. The course of the disease with the presence of diarrhea and vomiting without fever and other classical manifestations is described. The purpose is to review the scientific literature on the analysis of the leading pathogenetic factors in the formation of intestinal syndrome in a new coronavirus infection. Material and methods. The scientific literature was searched in the Web of Science, Scopus, PubMed and RSCI databases for the following keywords: coronavirus infection, intestinal syndrome. Search depth - 3 years. Results. The study revealed clinical manifestations of the gastrointestinal tract (gastrointestinal tract) in COVID-19 infection, their main mechanisms and the frequency of occurrence of certain symptoms in practice

гастроэнтерологические пораженияCOVID-19диареятошнотарвотаосложнения COVID-инфекцииgastroenterological disordersCOVID-19diarrheanauseavomitingcomplications of COVID infectionReferencesDiagnosis and treatment of coronavirus infection COVID 19: a clinical protocol approved by the joint commission on the quality of medical services of the Ministry of Health of the Republic of Kazakhstan. Minutes No. 92 dated May 6, 2020. (in Russ.)@@ Диагностика и лечение коронавирусной инфекции COVID 19: клинический протокол, одобренный объединенной комиссией по качеству медицинских услуг МЗ РК. Протокол № 92. от 6.05.2020.Diagnosis and treatment of coronavirus infection COVID 19: a clinical protocol approved by the joint commission on the quality of medical services of the Ministry of Health of the Republic of Kazakhstan. Minutes No. 92 dated May 6, 2020. (in Russ.)@@ Диагностика и лечение коронавирусной инфекции COVID 19: клинический протокол, одобренный объединенной комиссией по качеству медицинских услуг МЗ РК. Протокол № 92. от 6.05.2020.Korovin A. E., Novitskiy A. A., Makarov D. A. Acute respiratory distress syndrome. Current state of the problem. Clinical Pathophysiology. 2018;(2):32-41. (in Russ.)@@ Коровин А. Е., Новицкий А. А., Макарова Д. А. Острый респираторный дис-тресс-синдром. Современное состояние проблемы // Клиническая патофизио-логия.2018. № 2. С. 32-41.Korovin A. E., Novitskiy A. A., Makarov D. A. Acute respiratory distress syndrome. Current state of the problem. Clinical Pathophysiology. 2018;(2):32-41. (in Russ.)@@ Коровин А. Е., Новицкий А. А., Макарова Д. А. Острый респираторный дис-тресс-синдром. Современное состояние проблемы // Клиническая патофизио-логия.2018. № 2. С. 32-41.Kamkin E. G. Prevention, diagnosis and treatment of a new coronavirus infection (COVID 19): temporary guidelines of the Ministry of Health of the Russian Federation. Moscow, 2020. 164p. (in Russ.)@@ Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID 19)/ под.ред. Е. Г. Камкина: временные методические рекомендации МЗ РФ. Москва, 2020. 164с.Kamkin E. G. Prevention, diagnosis and treatment of a new coronavirus infection (COVID 19): temporary guidelines of the Ministry of Health of the Russian Federation. Moscow, 2020. 164p. (in Russ.)@@ Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID 19)/ под.ред. Е. Г. Камкина: временные методические рекомендации МЗ РФ. Москва, 2020. 164с.Guo Т., Yongzhen F., Chen М., Wu Х., Zhang L., He Т., Wang H., Wan J., Wang Х., Lu Z. Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Jul 1;5(7):811-818. doi: 10.1001/jamacardio.2020.1017.Guo Т., Yongzhen F., Chen М., Wu Х., Zhang L., He Т., Wang H., Wan J., Wang Х., Lu Z. Cardiovascular Implications of Fatal Outcomes of Patients with Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Jul 1;5(7):811-818. doi: 10.1001/jamacardio.2020.1017.Lee P. I., Hu YL., Chen P. Y., Huang Y.-C., Hsueh P.-R. Are children less sus-ceptible to COVID-19? J Microbiol Immunol Infect. 2020 Jun;53(3):371-372. doi: 10.1016/j.jmii.2020.02.011.Lee P. I., Hu YL., Chen P. Y., Huang Y.-C., Hsueh P.-R. Are children less sus-ceptible to COVID-19? J Microbiol Immunol Infect. 2020 Jun;53(3):371-372. doi: 10.1016/j.jmii.2020.02.011.[Diagnosis and treatment of coronaviruous infection COVID 19: clinical protocol approved by the Joint Commission on the Quality of Medical Services of the Ministry of Health of the Republic of Kazakhstan. Minutes 92 dated 6.05.2020]. (in Russ.)[Diagnosis and treatment of coronaviruous infection COVID 19: clinical protocol approved by the Joint Commission on the Quality of Medical Services of the Ministry of Health of the Republic of Kazakhstan. Minutes 92 dated 6.05.2020]. (in Russ.)Korovin A. E., Novitskiy A. A., Makarov D. A. Acute respiratory distress syndrome. Current state of the problem. Clinical Pathophysiology. 2018;(2):32-41. (in Russ.)Korovin A. E., Novitskiy A. A., Makarov D. A. Acute respiratory distress syndrome. Current state of the problem. Clinical Pathophysiology. 2018;(2):32-41. (in Russ.)Aleksandrovich Yu.S. [Features of clinical manifestations and treatment of disease caused by a new coronavirus infection (COVID 19) in children]. Moscow. MZ RF Publ. 2020. 43p. (in Russ.)Aleksandrovich Yu.S. [Features of clinical manifestations and treatment of disease caused by a new coronavirus infection (COVID 19) in children]. Moscow. MZ RF Publ. 2020. 43p. (in Russ.)Bassetti M. The Novel Chinese Coronavirus (2019 -nCoV) Infections challenges for fighting the strom. Eur. J. Clin. Invest. 2020. № 1. doi: 10.1111/ eci13209.Bassetti M. The Novel Chinese Coronavirus (2019 -nCoV) Infections challenges for fighting the strom. Eur. J. Clin. Invest. 2020. № 1. doi: 10.1111/ eci13209.Cao Y., Liu X., Xiong L., Cai K. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: a systematic review and meta-analysis. J. Med. Virol. 2020 Sep;92(9):1449-1459. doi: 10.1002/jmv.25822.Cao Y., Liu X., Xiong L., Cai K. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: a systematic review and meta-analysis. J. Med. Virol. 2020 Sep;92(9):1449-1459. doi: 10.1002/jmv.25822.Gu J., Han B., Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. Gastroenterology. 2020 May;158(6):1518-1519. doi: 10.1053/j.gastro.2020.02.054.Gu J., Han B., Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. Gastroenterology. 2020 May;158(6):1518-1519. doi: 10.1053/j.gastro.2020.02.054.Walls A. C., Park Y. J., Tortorici M. A., Wall A., McGuire A. T., Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;180:1-12. doi: 10.1016/j.cell.2020.02.058Walls A. C., Park Y. J., Tortorici M. A., Wall A., McGuire A. T., Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;180:1-12. doi: 10.1016/j.cell.2020.02.058Temporary methodological recommendations of the Ministry of Health of Russia. «Prevention, diagnostics and treatment of new coronavirus infection (COVID-19)». (in Russ.)Temporary methodological recommendations of the Ministry of Health of Russia. «Prevention, diagnostics and treatment of new coronavirus infection (COVID-19)». (in Russ.)Yachou Y., El Idrissi A., Belapasov V., Ait Benali S. Neuroinvasion, neurotropic, and neuroinfl ammatory events of SARSCoV-2: understanding the neurological manifestations in COVID19 patients. Neurol Sci. 2020; 41: 2657-69. doi: 10.1007/s10072-020-04575-3.Yachou Y., El Idrissi A., Belapasov V., Ait Benali S. Neuroinvasion, neurotropic, and neuroinfl ammatory events of SARSCoV-2: understanding the neurological manifestations in COVID19 patients. Neurol Sci. 2020; 41: 2657-69. doi: 10.1007/s10072-020-04575-3.Wang X., Fang J., Zhu Y., Chen L., Ding F., Zhou R., et al. Clinical characteristics of non-critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang Hospital. Clin Microbiol Infect. 2020; 26 (8): 1063-8. doi: 10.1016/j.cmi.2020.03.032.Wang X., Fang J., Zhu Y., Chen L., Ding F., Zhou R., et al. Clinical characteristics of non-critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang Hospital. Clin Microbiol Infect. 2020; 26 (8): 1063-8. doi: 10.1016/j.cmi.2020.03.032.Agarwal A., Chen A., Ravindran N., To C., Thuluvath P. J. Gastrointestinal and Liver Manifestations of COVID-19. J Clin Exp Hepatol. 2020; 10 (3): 263-5. doi: 10.1016/j.jceh.2020.03.001.Agarwal A., Chen A., Ravindran N., To C., Thuluvath P. J. Gastrointestinal and Liver Manifestations of COVID-19. J Clin Exp Hepatol. 2020; 10 (3): 263-5. doi: 10.1016/j.jceh.2020.03.001.Pan L., Mu M., Yang P., Sun Y., Wang R., Yan J., et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol. 2020; 115 (5): 766-73. doi: 10.14309/ajg.0000000000000620.Pan L., Mu M., Yang P., Sun Y., Wang R., Yan J., et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol. 2020; 115 (5): 766-73. doi: 10.14309/ajg.0000000000000620.Jin X., Lian J. S., Hu J. H., et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020 Jun;69(6):1002-1009. doi: 10.1136/gutjnl-2020-320926.Jin X., Lian J. S., Hu J. H., et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020 Jun;69(6):1002-1009. doi: 10.1136/gutjnl-2020-320926.Wang F., Zheng S., Zheng C., Sun X. Attaching clinical signifi cance to COVID-19-associated diarrhea. Life Sci. 2020; 260: 118312. doi: 10.1016/j.lfs.2020.118312Wang F., Zheng S., Zheng C., Sun X. Attaching clinical signifi cance to COVID-19-associated diarrhea. Life Sci. 2020; 260: 118312. doi: 10.1016/j.lfs.2020.118312Song Y., Zhang M., Yin L., Wang K., Zhou Y., Zhou M., et al. COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2).Int J Antimicrob Agents. 2020; 56 (2): 106080. doi: 10.1016/j.ij antimicag.2020.106080.Song Y., Zhang M., Yin L., Wang K., Zhou Y., Zhou M., et al. COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2).Int J Antimicrob Agents. 2020; 56 (2): 106080. doi: 10.1016/j.ij antimicag.2020.106080.Chau T. N., Lee K. C., Yao H., et al. SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology. 2004 Feb;39(2):302-10. doi: 10.1002/hep.20111.Chau T. N., Lee K. C., Yao H., et al. SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology. 2004 Feb;39(2):302-10. doi: 10.1002/hep.20111.Lee C., Huo T.-I., Huanga Y.-H. Gastrointestinal and liver manifestations in patients with COVID-19. J. Chin. Med. Assoc. 2020 Jun;83(6):521-523. doi: 10.1097/JCMA.0000000000000319.Lee C., Huo T.-I., Huanga Y.-H. Gastrointestinal and liver manifestations in patients with COVID-19. J. Chin. Med. Assoc. 2020 Jun;83(6):521-523. doi: 10.1097/JCMA.0000000000000319.Fan Z., Chen L., Li J., et al. Clinical Features of COVID-19-Related Liver Functional Abnormality. Clin Gastroenterol Hepatol. 2020 Jun;18(7):1561-1566. doi: 10.1016/j.cgh.2020.04.002.Fan Z., Chen L., Li J., et al. Clinical Features of COVID-19-Related Liver Functional Abnormality. Clin Gastroenterol Hepatol. 2020 Jun;18(7):1561-1566. doi: 10.1016/j.cgh.2020.04.002.Zhang C., Shi L., Wang F.-S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430. doi: 10.1016/S2468-1253(20)30057-1.Zhang C., Shi L., Wang F.-S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430. doi: 10.1016/S2468-1253(20)30057-1.Guan W.J., Ni Z. Y., Hu Y., et al. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032.Guan W.J., Ni Z. Y., Hu Y., et al. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032.Wang F., Wang H., Fan J., Zhang Y., et al. Pancreatic Injury Patterns in Patients With Coronavirus Disease 19 Pneumonia. Gastroenterology. 2020;159(1):367-370. doi: 10.1053/j.gastro.2020.03.055.Wang F., Wang H., Fan J., Zhang Y., et al. Pancreatic Injury Patterns in Patients With Coronavirus Disease 19 Pneumonia. Gastroenterology. 2020;159(1):367-370. doi: 10.1053/j.gastro.2020.03.055.Wang F., Wang H., Fan J., et al. Pancreatic injury patterns in patients with coronavirus disease 19 pneumonia. Gastroenterology. 2020 Jul;159(1):367-370. doi: 10.1053/j.gastro.2020.03.055.Wang F., Wang H., Fan J., et al. Pancreatic injury patterns in patients with coronavirus disease 19 pneumonia. Gastroenterology. 2020 Jul;159(1):367-370. doi: 10.1053/j.gastro.2020.03.055.Lax S. F., Skok K., Zechner P., et al. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series. Ann.Intern. Med. 2020 Sep 1;173(5):350-361. doi: 10.7326/M20-2566.Lax S. F., Skok K., Zechner P., et al. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series. Ann.Intern. Med. 2020 Sep 1;173(5):350-361. doi: 10.7326/M20-2566.Dirweesh A., Li Y., Trikudanathan G. et al. Clinical outcomes of acute pancreatitis in patients with coronavirus disease 2019. Gastroenterology. 2020 Nov;159(5):1972-1974. doi: 10.1053/j.gastro.2020.07.038.Dirweesh A., Li Y., Trikudanathan G. et al. Clinical outcomes of acute pancreatitis in patients with coronavirus disease 2019. Gastroenterology. 2020 Nov;159(5):1972-1974. doi: 10.1053/j.gastro.2020.07.038.

The authors declare that there are no conflicts of interest present.